SPEED-MEDICAL-SAE
8.9.2021 16:17:10 CEST | Business Wire | Press release
Speed Medical Company (EGX: SPMD), today announced a EGP 1.57 billion capital commitment from GEM Global Yield LLC SCS ("GGY"), the Luxembourg based private alternative investment group.
Under the agreement, GGY will provide Speed Medical Co. (SPMD) with a Share Subscription Facility of up to EGP 1,570 million for a 36-month term to use at its discretion, subject to agreed upon terms. The company will have no minimum drawdown obligation and is authorized to utilize the facility on an as-need basis over the life of the agreement.
“We are pleased to receive what we believe is potentially lower cost and less dilutive financing, as the company controls the timing and amount of each drawdown. The new facility will provide financing that can be deployed for acquisitions, our aggressive expansion plans, new venture financing as well as consolidating current bank obligations. The facility will help the company to maintain its growth and at the same time start distributing cash dividends to its shareholders commencing in the coming year,” Chairman of SPMD, Mahmoud Lasheen, was quoted.
About Speed Medical SAE
Speed Medical SAE (known as: Speed Medical), is a publicly listed company on the Egyptian Stock Exchange (EGX) since March 2019. Speed Medical operates in the Health Care Sector. Speed Medical is based in Cairo, Egypt and was Established in December 2015. Speed Medical is currently operating a large scale medical lab chain in Egypt under the name “Speed Lab”. In addition, SPMD operates a series of polyclinics under the name “Speed Clinic”, has established a 140-bed hospital in East Cairo, and has announced partnerships that include COVID19 drive thru testing sites and Vaccines sites.
About GEM
Global Emerging Markets (“GEM”) is a $3.4 billion, Luxembourg-based private alternative investment group with offices in Paris, New York and The Bahamas. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 480 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005801/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company Sign a 3.2 billion SAR Joint Venture Agreement to Develop and Deliver Expo Village14.9.2026 11:42:00 CEST | Press release
Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company (MAHR) have signed a 3.2 billion SAR joint venture agreement for the development and delivery of the Expo Village, the residential community for Expo 2030 Riyadh. The agreement represents the first joint venture milestone for Expo 2030 Riyadh and reinforces itscommitment to partnering with the private sector to unlock economic opportunities and create lasting value, both in the lead-up to the Expo and well beyond the event itself. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914576734/en/ Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company (MAHR) have signed a 3.2 billion SAR joint venture agreement for the development and delivery of the Expo Village, the residential community for Expo 2030 Riyadh The Expo Village will provide purpose-built accommodation for Official Participants and delegations within a fully integrated sustainable district. Designed to
Motive Announces Entitlement Server General Availability for iPhone Duo, iPhone 18 Pro and iPhone 18 Pro Max14.9.2026 11:00:00 CEST | Press release
A launch-ready, cloud-native platform that lets operators support the latest iPhone models from day one. Motive, a global leader in mobile device and connectivity management, today announced the general availability of Motive Entitlement Server support for iPhone Duo and the iPhone 18 series. Ahead of Apple’s announcement, Motive invested in the platform capabilities needed to support the new devices at launch. As a result, operators can support the new iPhone product families without waiting for additional platform development. The release provides comprehensive support for entitlement applications aligned with GSMA standards and interoperates with iOS and Android device ecosystems. This includes iPhone Handoff, which lets customers of supported carriers switch seamlessly between two iPhones while using a single phone number. “Apple’s latest announcement marks another important step toward an eSIM-first future,” said Jeevithan Muttu, SVP and General Manager of Device Management at Mot
Venture Global and China Gas Announce New Long-Term LNG Agreement14.9.2026 10:30:00 CEST | Press release
Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030.This SPA brings Venture Global’s current long-term offtake with China Gas, to 2.5 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to expand our LNG partnership with China Gas, a leading natural gas operator in China, supplying the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects," said Venture Global CEO Mike Sabel. “We are pleased to deepen our long-standing partnership with Venture Global through this new agreement,” said Mr. Liu Ming Hui, Chairman and President of China Gas. “It further strengthens our portfolio
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom